Core Insights - Hikma achieved significant growth in 2025, launching 84 products and becoming the largest pharmaceutical company in MENA by sales for the first time in its history [1] - The company is focusing on strengthening its injectable business and has begun implementing leadership changes to address challenges [1] Business Performance - The Branded division is recognized as a best-in-class operation in MENA, characterized by local market expertise, a broad portfolio, and strong customer relationships [2] - Hikma Rx has gained importance, focusing on growth in higher-value areas such as complex medicines and CMO services [2] Market Position - Hikma Rx is positioned as one of the leading U.S. domestic producers of generic medicines, contributing positively to the U.S. healthcare landscape [3] - The injectable segment maintains strong margins, but continued investment is necessary to sustain growth [3]
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
Seeking Alpha·2026-02-28 07:27